WuXi Biologics Statistics
Total Valuation
WuXi Biologics has a market cap or net worth of 12.46 billion. The enterprise value is 12.33 billion.
| Market Cap | 12.46B |
| Enterprise Value | 12.33B |
Important Dates
The next estimated earnings date is Friday, March 21, 2025.
| Earnings Date | Mar 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -1.28% |
| Shares Change (QoQ) | -2.12% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.50B |
Valuation Ratios
The trailing PE ratio is 34.41.
| PE Ratio | 34.41 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 2.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.84, with an EV/FCF ratio of -287.15.
| EV / Earnings | 34.03 |
| EV / Sales | 5.21 |
| EV / EBITDA | 18.84 |
| EV / EBIT | 25.86 |
| EV / FCF | -287.15 |
Financial Position
The company has a current ratio of 2.91, with a Debt / Equity ratio of 0.10.
| Current Ratio | 2.91 |
| Quick Ratio | 2.40 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.96 |
| Debt / FCF | -14.64 |
| Interest Coverage | 23.35 |
Financial Efficiency
Return on equity (ROE) is 7.20% and return on invested capital (ROIC) is 4.61%.
| Return on Equity (ROE) | 7.20% |
| Return on Assets (ROA) | 3.98% |
| Return on Invested Capital (ROIC) | 4.61% |
| Return on Capital Employed (ROCE) | 7.00% |
| Revenue Per Employee | 189,417 |
| Profits Per Employee | 29,128 |
| Employee Count | 12,740 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 5.35 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +24.53% in the last 52 weeks. The beta is 0.58, so WuXi Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.58 |
| 52-Week Price Change | +24.53% |
| 50-Day Moving Average | 4.92 |
| 200-Day Moving Average | 3.80 |
| Relative Strength Index (RSI) | 59.92 |
| Average Volume (20 Days) | 49,164 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, WuXi Biologics had revenue of 2.36 billion and earned 362.21 million in profits. Earnings per share was 0.08.
| Revenue | 2.36B |
| Gross Profit | 910.60M |
| Operating Income | 474.76M |
| Pretax Income | 502.72M |
| Net Income | 362.21M |
| EBITDA | 625.87M |
| EBIT | 474.76M |
| Earnings Per Share (EPS) | 0.08 |
Balance Sheet
The company has 1.31 billion in cash and 628.49 million in debt, giving a net cash position of 682.75 million.
| Cash & Cash Equivalents | 1.31B |
| Total Debt | 628.49M |
| Net Cash | 682.75M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.14B |
| Book Value Per Share | 1.35 |
| Working Capital | 1.79B |
Cash Flow
In the last 12 months, operating cash flow was 443.07 million and capital expenditures -486.00 million, giving a free cash flow of -42.93 million.
| Operating Cash Flow | 443.07M |
| Capital Expenditures | -486.00M |
| Free Cash Flow | -42.93M |
| FCF Per Share | n/a |
Margins
Gross margin is 38.66%, with operating and profit margins of 20.16% and 15.38%.
| Gross Margin | 38.66% |
| Operating Margin | 20.16% |
| Pretax Margin | 21.34% |
| Profit Margin | 15.38% |
| EBITDA Margin | 26.57% |
| EBIT Margin | 20.16% |
| FCF Margin | n/a |
Dividends & Yields
WuXi Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.28% |
| Shareholder Yield | 1.28% |
| Earnings Yield | 2.91% |
| FCF Yield | -0.34% |
Stock Splits
The last stock split was on December 10, 2020. It was a forward split with a ratio of 3.
| Last Split Date | Dec 10, 2020 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |